Trade Ionis Pharmaceuticals, Inc. - IONS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.29 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 29.48 |
| Open | 28.99 |
| 1-Year Change | -31.63% |
| Day's Range | 28.65 - 29.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 29.48 | 0.50 | 1.73% | 28.98 | 29.69 | 28.53 |
| Apr 23, 2025 | 29.02 | -0.43 | -1.46% | 29.45 | 30.01 | 28.98 |
| Apr 22, 2025 | 28.97 | 1.28 | 4.62% | 27.69 | 29.19 | 27.69 |
| Apr 21, 2025 | 28.39 | 0.75 | 2.71% | 27.64 | 28.96 | 27.54 |
| Apr 17, 2025 | 28.34 | 0.37 | 1.32% | 27.97 | 28.63 | 27.90 |
| Apr 16, 2025 | 28.29 | 0.39 | 1.40% | 27.90 | 28.75 | 27.43 |
| Apr 15, 2025 | 28.21 | -0.21 | -0.74% | 28.42 | 28.85 | 28.07 |
| Apr 14, 2025 | 28.55 | 0.56 | 2.00% | 27.99 | 28.95 | 27.63 |
| Apr 11, 2025 | 27.84 | 1.64 | 6.26% | 26.20 | 27.89 | 26.11 |
| Apr 10, 2025 | 26.64 | -0.31 | -1.15% | 26.95 | 27.12 | 25.58 |
| Apr 9, 2025 | 27.63 | 2.73 | 10.96% | 24.90 | 27.81 | 23.83 |
| Apr 8, 2025 | 25.21 | -2.49 | -8.99% | 27.70 | 27.91 | 24.67 |
| Apr 7, 2025 | 27.48 | 0.95 | 3.58% | 26.53 | 27.49 | 25.36 |
| Apr 4, 2025 | 25.95 | -1.58 | -5.74% | 27.53 | 28.36 | 25.95 |
| Apr 3, 2025 | 28.36 | 0.62 | 2.24% | 27.74 | 28.84 | 27.63 |
| Apr 2, 2025 | 28.68 | 1.78 | 6.62% | 26.90 | 28.73 | 26.90 |
| Apr 1, 2025 | 27.20 | -2.78 | -9.27% | 29.98 | 29.98 | 27.04 |
| Mar 31, 2025 | 29.96 | -0.17 | -0.56% | 30.13 | 30.34 | 29.43 |
| Mar 28, 2025 | 30.97 | 0.60 | 1.98% | 30.37 | 31.28 | 30.37 |
| Mar 27, 2025 | 31.55 | 0.15 | 0.48% | 31.40 | 31.71 | 30.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Ionis Pharmaceuticals Company profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein. It is also developing inotersen, an antisense drug Ionis to treat patients with hereditary transthyretin amyloidosis; and volanesorsen, an antisense drug for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. In addition, the company is developing drugs for various indications, such as cardiometabolic diseases caused by lipid disorders; cardiovascular disease, clotting disorders, and Alzheimer's and Parkinson's diseases; and acromegaly, amyotrophic lateral sclerosis, beta-thalassemia, and Huntington's disease. Ionis Pharmaceuticals, Inc. has a collaboration agreement with AstraZeneca to discover and develop antisense therapies for treating cardiovascular and metabolic diseases, and cancer; and Biogen Inc. to develop and commercialize therapies for neurological disorders, SMA, and neurodegenerative diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.| Industry: | Biotechnology & Medical Research (NEC) |
2855 Gazelle Court
CARLSBAD
CALIFORNIA 92010
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com